AT149124B - Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. - Google Patents
Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes.Info
- Publication number
- AT149124B AT149124B AT149124DA AT149124B AT 149124 B AT149124 B AT 149124B AT 149124D A AT149124D A AT 149124DA AT 149124 B AT149124 B AT 149124B
- Authority
- AT
- Austria
- Prior art keywords
- agent
- abolishing
- inhibiting
- mucous membranes
- manufacture
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung eines Mittels zur Hemmung und Aufhebung der pathologischen Sekretion der Nasenschleimhäute. fie Jjjimaung oezient sien aut em venanren zur Herstellung eines Mittels, dureh weiches die pathologisch Sekretion der Nasenschleimhaut gehemmt und aufgehoben wird. Versuche, welche angestellt wurden, haben ergeben, dass Schlangengift, wie solches von Crotalos, Kobra, Vipern, in einer geeigneten Salbengrundlage die Eigenschaft besitzt, verschiedene Nasenleiden zu heilen. Gute Erfolge wurden beispielsweise erzielt bei Rhinitis vasomotoria, Heuschnupfen, Rhinitis ehronica und akutem Schnupfen. Auch bei schwerer Ozaena hat sich das Mittel bewährt.
Es genügt, geringe Mengen des Schlangengiftes der Salbengrundlage einzuverleiben. Dasselbe kann vorteilhaft mit Stoffen kombiniert werden, welche die Resorption durch die Haut fördern, wie z. B. Saponin, Triäthanolamin. Es können auch Zusätze von Mitteln erfolgen, welche resorbiert werden und dadurch die Giftwirkung fördern, wie z. B. Salizylsäure und ihre Salze. Ferner können auch solche Zusätze erfolgen, welche gleichzeitig eine Hyperämisierung hervorrufen. Je nach Umständen kann hiedurch der therapeutische Effekt entsprechend eingeregelt werden.
Beispielsweise kann die Salbe in der Weise hergestellt werden, dass in 200 CM3 Wasser 1 g des in üblicher Weise beschaffen Schlangengiftes versetzt und diese Lösung mit weiteren 200 g Euzerin,
EMI1.1
zweimal täglich an beiden Armen des Patienten abwechselnd in die Haut eingerieben werden. Je nach der Schwere des Krankheitszustandes wird der Heilungseffekt in kürzester oder nach längerer Zeit in Erscheinung treten.
**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.
<Desc / Clms Page number 1>
Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. The Jjjimaung oezient sien aut em venanren for the production of an agent by which the pathological secretion of the nasal mucous membrane is inhibited and canceled. Experiments which have been carried out have shown that snake venom, such as that of Crotalos, cobra, vipers, in a suitable ointment base has the property of curing various nasal ailments. Good results have been achieved, for example, with rhinitis vasomotoria, hay fever, rhinitis ehronica and acute rhinitis. The remedy has also proven itself in severe ozaena.
It is sufficient to incorporate small amounts of the snake venom into the ointment base. The same can advantageously be combined with substances that promote absorption through the skin, such as. B. saponin, triethanolamine. There can also be additions of agents which are absorbed and thereby promote the poisonous effect, such as. B. Salicylic acid and its salts. Furthermore, such additives can also be made which simultaneously cause hyperaemia. Depending on the circumstances, the therapeutic effect can be adjusted accordingly.
For example, the ointment can be prepared in such a way that 1 g of the snake venom obtained in the usual way is added to 200 cm3 of water and this solution with another 200 g of Euzerin,
EMI1.1
alternately rubbed into the skin on both arms of the patient twice a day. Depending on the severity of the disease, the healing effect will appear in a very short time or after a longer period of time.
** WARNING ** End of DESC field may overlap beginning of CLMS **.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT149124T | 1936-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AT149124B true AT149124B (en) | 1937-04-10 |
Family
ID=3645473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT149124D AT149124B (en) | 1936-06-09 | 1936-06-09 | Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. |
Country Status (1)
Country | Link |
---|---|
AT (1) | AT149124B (en) |
-
1936
- 1936-06-09 AT AT149124D patent/AT149124B/en active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT149124B (en) | Process for the manufacture of an agent for inhibiting and abolishing pathological secretion of the nasal mucous membranes. | |
AT142023B (en) | Process for the manufacture of an agent for protecting the epidermis against infection and for healing skin diseases. | |
AT200262B (en) | Process for the production of durable water-containing solutions of pure cardiac glycosides | |
WO1991004752A1 (en) | Eye-drops | |
DE463805C (en) | Process for the preparation of durable, sterilizable solutions which contain phosphorus in organic bonds and bound gold | |
AT107599B (en) | Process for the preparation of durable, sterilizable solutions, which contain phosphorus in organic bonds as well as bound gold. | |
AT157575B (en) | Process for the production of undecomposed, sterilizable drug solutions from the double compound theophylline-piperazine. | |
US2025399A (en) | Topical anzesthetic | |
DE431847C (en) | Process for the production of intravenous injectable preparations against bilharzia | |
AT129939B (en) | Process for the production of a wound ointment. | |
DE752680C (en) | Anion exchange | |
DE695034C (en) | Process for the preparation of durable solutions of p-aminobenzenesulfonamide | |
AT112734B (en) | Process for the preparation of monocamphorates of the Solanaceae alkaloids. | |
DE576445C (en) | Process for the production of primula acid (primula saponin) from primula species | |
DE427668C (en) | Process for the preparation of quinine solutions suitable for subcutaneous injections | |
DE544678C (en) | Disinfectants | |
AT133895B (en) | Process for the preparation of acylaminobenzenestibinic acids. | |
DE819127C (en) | Process for the preparation of a therapeutic bath against skin eczema | |
AT133143B (en) | Process for the preparation of readily soluble sodium salts of 4-oxy-3-acylaminobenzolaric acids (1) or their substitution products. | |
AT142163B (en) | Process for the manufacture of preparations for sunlight treatment. | |
DE1518102C3 (en) | Process for the preparation of a pure water-soluble condensation product suitable for therapeutic purposes from m-cresol sulfonic acid and formaldehyde | |
AT132570B (en) | Process for the production of primula saponin from primula species. | |
AT166471B (en) | ||
AT68796B (en) | Process for the production of tanning preparations which are easily soluble in cold water. | |
AT203000B (en) | Process for the preparation of new salts of 4,6-dioxyisophthalic acid and 5-halogen (especially 5-iodine) - 4,6-dioxyisophthalic acid |